Navigation Links
Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Date:1/4/2012

BETHLEHEM, Pa., Jan. 4, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Edward L. Erickson, president and CEO of Saladax, will be presenting at the Biotech Showcase™ 2012 Conference being held in San Francisco, CA.  The presentation will be given on Wednesday, January 11, 2012 at 3:45 p.m. PST on the fourth floor of the Parc 55 Wyndham San Francisco Union Square hotel.  Mr. Erickson will provide an overview of the company's business, including its products, sales and marketing activities, strategic alliances and finances.

About My5-FU™

Saladax's first commercially available test for innovative dose management, My5-FU, measures levels of 5-flourouracil (5-FU), a widely prescribed chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and other side effects.

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems.  In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology. In addition the company is finalizing development of its next two oncology drug assays, for paclitaxel and docetaxel. Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.

Saladax Biomedical, Inc.
Edward L. Erickson
President and Chief Executive Officer
eerickson@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. Appoints Li Zhang, M.D., to Scientific Advisory Board
2. Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City
3. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
4. Saladax Biomedical, Inc. Announces European Commercialization Team
5. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
6. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
7. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
8. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
10. Cardium to Present at Upcoming Investor Conferences
11. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2019)... ... , ... Today, at the BIO World Congress on Industrial Biotechnology ... announced the winners of the Consider Corn Challenge II. Three winners were chosen, each ... produce biobased materials. , “Corn is a sustainable, abundant and affordable industrial ...
(Date:6/26/2019)... ... ... Alice Branton today released research results from preclinical trials on the beneficial impact ... to be beneficial for treating Hypomagnesemia. , The preclinical trial shows:, ... Over 142% increase in particle size , Over 3% alteration ...
(Date:6/12/2019)... EGG HARBOR TOWNSHIP, N.J. (PRWEB) , ... June ... ... premier manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, ... partnership agreement with Shanghai Zillion has been signed. The agreement will grant exclusive ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... will add 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed ... DeepDyve’s continually expanding library of more than 20 million articles, sourced from more ...
Breaking Biology Technology:
(Date:8/21/2019)... ... 20, 2019 , ... Scientists ranked New England Biolabs number ... the survey in 2016. The results are published in the newest report, ... Science and Medicine Group. More than 800 life scientists were asked to rank ...
(Date:8/15/2019)... ... August 15, 2019 , ... Deep Science Ventures ... Food and Agriculture practice, a new unit dedicated to building 100 companies over the ... raw materials and supply chains. , Deep Science Ventures was founded to create ...
(Date:8/15/2019)... ... August 15, 2019 , ... Make IVD tests ... routine tasks. That was the message at the world's largest gathering of laboratory ... American Association for Clinical Chemistry (AACC) Annual Scientific Meeting was held in Anaheim, ...
Breaking Biology News(10 mins):